Morgan Stanley I Mab Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in I Mab stock. As of the latest transaction made, Morgan Stanley holds 58,295 shares of IMAB stock, worth $224,435. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,295

Previous 34,817 67.43%

Holding current value

$224,435

Previous $28,000 403.57%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$0.62 - $2.8 $14,556 - $65,738	23,478 Added 67.43%	58,295 $141,000
Q1 2025 May 15, 2025	SELL	$0.8 - $1.1 $2.81 Million - $3.86 Million	-3,508,567 Reduced 99.02%	34,817 $28,000
Q4 2024 Feb 14, 2025	BUY	$0.85 - $1.6 $2.99 Million - $5.62 Million	3,512,737 Added 11461.93%	3,543,384 $3.01 Million
Q3 2024 May 14, 2025	BUY	$1.03 - $1.72 $17,270 - $28,839	16,767 Added 120.8%	30,647 $38,000
Q3 2024 Nov 14, 2024	BUY	$1.03 - $1.72 $17,270 - $28,839	16,767 Added 120.8%	30,647 $38,000
Q2 2024 May 14, 2025	SELL	$1.58 - $1.9 $5.58 Million - $6.71 Million	-3,529,504 Reduced 99.61%	13,880 $23,000
Q2 2024 Oct 17, 2024	BUY	$1.58 - $1.9 $5,958 - $7,164	3,771 Added 37.3%	13,880 $23,000
Q2 2024 Aug 14, 2024	BUY	$1.58 - $1.9 $5,958 - $7,164	3,771 Added 37.3%	13,880 $23,000
Q1 2024 Oct 17, 2024	SELL	$1.54 - $2.37 $5,807 - $8,937	-3,771 Reduced 27.17%	10,109 $18,000
Q1 2024 Aug 16, 2024	SELL	$1.54 - $2.37 $780,143 - $1.2 Million	-506,587 Reduced 98.04%	10,109 $18,000
Q1 2024 May 15, 2024	SELL	$1.54 - $2.37 $780,143 - $1.2 Million	-506,587 Reduced 98.04%	10,109 $18,000
Q4 2023 Aug 16, 2024	BUY	$1.21 - $1.9 $608,407 - $955,350	502,816 Added 3622.59%	516,696 $981,000
Q4 2023 Feb 13, 2024	SELL	$1.21 - $1.9 $571,101 - $896,771	-471,985 Reduced 47.74%	516,696 $981,000
Q3 2023 Nov 15, 2023	BUY	$1.18 - $3.06 $642,499 - $1.67 Million	544,491 Added 122.58%	988,681 $1.31 Million
Q2 2023 Aug 14, 2023	SELL	$2.95 - $3.85 $1.98 Million - $2.58 Million	-670,982 Reduced 60.17%	444,190 $1.33 Million
Q1 2023 May 15, 2023	SELL	$3.08 - $7.39 $1.47 Million - $3.52 Million	-476,099 Reduced 29.92%	1,115,172 $3.86 Million
Q4 2022 Feb 14, 2023	SELL	$3.22 - $4.86 $970,936 - $1.47 Million	-301,533 Reduced 15.93%	1,591,271 $6.65 Million
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $1.94 Million - $5.96 Million	-483,164 Reduced 20.34%	1,892,804 $7.59 Million
Q2 2022 Oct 27, 2022	BUY	$8.27 - $18.43 $6.22 Million - $13.9 Million	751,560 Added 46.27%	2,375,968 $26.8 Million
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $6.22 Million - $13.9 Million	751,560 Added 46.27%	2,375,968 $26.8 Million
Q1 2022 Oct 27, 2022	SELL	$12.54 - $46.93 $9.42 Million - $35.3 Million	-751,560 Reduced 31.63%	1,624,408 $26.4 Million
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $2.08 Million - $7.79 Million	166,052 Added 11.39%	1,624,408 $26.4 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $1.11 Million - $1.83 Million	24,544 Added 1.71%	1,458,356 $69.1 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $82 Million - $121 Million	1,433,812 New	1,433,812 $104 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

14.2M

Call Options Held

10.2K

Put Options Held

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $320M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account